Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care

NCT07897890 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07897890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care
Lead sponsor
Indiana University
Phase
Not applicable
Overall status
Completed
Start date
June 6, 2024
Completion date
August 8, 2024
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, obesity & overweight

Arms

As registered; 1 arm.

  • THRIVE NOW ExperimentalTHRIVE NOW

    Across eight weekly 2-hour group sessions, Black or African American breast cancer survivors with obesity learn and practice behavioral weight-management skills, including healthy eating, physical activity, self-monitoring, and goal setting. Participants also learn adaptive coping skills, including acceptance of difficult thoughts, feelings, and bodily sensations; present-moment awareness through mindfulness practices; clarification of personal values; and setting goals consistent with those values. Through in-session and home practice, participants develop strategies for responding more adaptively to challenges such as distress and urges that may interfere with weight-management goals. Participants receive handouts on session topics and are asked to track multiple behaviors (e.g., food intake, physical activity, sleep, etc.)

Primary endpoints

Registered primary outcome measures; 3 primary.

  • Number of participants enrolled and retained End of treatment at 8 weeks after baseline

    The percentage of breast cancer survivors who enrolled in the study and were retained at post-treatment (0-100%; higher percentage = more retained)

  • Attendance rates (Acceptability) Weekly attendance at each of the 8 THRIVE NOW sessions from baseline to last session

    Percentage of sessions that participants attended in person and/or made-up (0-100%; higher percentage = higher attendance)

  • Acceptability (Program Evaluation) End of treatment at 8 weeks after baseline

    Scores on the Treatment Acceptability/Adherence Scale (TAAS) (10-70; higher scores = greater acceptability/adherence ratings)

Lead sponsor's other trials

Indiana University, most recent start first.

Similar trials

Same condition (Weight Loss) and phase, most recent start first.